 Good morning, everybody. My name is Elena Patricci. I'm from the University of Siena in Italy and today I'm going to present you the second cycle master degree in Sustainable Industrial Pharmaceutical Biotechnology and the second level master in drug design and synthesis. I don't know how familiar are you with Italy, but Siena is located in the center of Italy in Tuscan region. And here you can find some beautiful pictures of power town and the countryside, which is famous especially for wines. Just to speak about some of the most famous ones, the Chianti one and the Brunello of Montalcino area. Siena is famous even for the university, which is one of the oldest in Italy. And we have different department and courses and the department of Biochemistry, Chemistry and Pharmacy that I'm a professor in. It has been recently awarded by the MIR, that's in the government with a grant as Department of Excellence in Italy. Our department and the University of Siena in general, it's in a territorially integrated ecosystem for research and education. And it's collaborating with the University Hospital, with the Tuscan region and the life science companies that are located all around Siena, as well as the important foundations of COVID organizations such as Tuscan Life Sciences. In Italy, the pharmaceutical company play a key role in the Italian economy, especially from the pharma export plants. If you look at this one from 2008 to 2018, you can see that Italy is the first one in Europe. And it's the one that it's mostly growing in the Midwest market for pharmaceuticals products, especially in Tuscany. Siena has been recognized as the so-called pharma valley, as we have more than 400 companies working in this field with seven billion production and two billion expert. We have many people working in boys in this field and a lot of investment in research, research and development. Everything, it's really connected with the University of Siena and particularly with our department, the department of biotechnology chemistry and pharmacy, which is directly working in this field, in the field of drug discovery. Particularly, we have three missions, the teaching, research and permission. For the teaching activity, as I will show you, we have different courses and for research, different fields of interest that are in between biology, chemistry and pharmacy. And so, we are all working on the bioeconomy, aquifood, therapeutics and diagnosis, as well as vaccines, bio-material and renewable energy. So, it's a cross-cutting design and the DBCF play a key role in the regional district. Here, you can find some of the research fields in which our department is involved, which are moving from post-genetic molecular mechanics and mechanisms of disease, medicine and chemistry, drug design and synthesis, molecular modeling, drug discovery, regulatory affairs and advanced analytical chemistry. And all are applied to different diseases, moving from cancer to real disease, neurological disease, nitrocellular, post-netrical and so on. So, for the teaching activity, we have more than 1,700 students in our department and we start from the EPS, which is the first level of education activity, moving to the bachelor. And we have a bachelor, which is in three years in chemical sciences, to first level master degree in chemistry and sustainable industrial pharmaceutical biotechnology, both are in English and a single-cycle master degree of five years pharmacy or in pharmaceutical and chemical technology. Then we have a school of specialization, here are some of the fantastic laboratories that we have in our department, this is our teaching. We have a school of specialization in clinical pharmacy, which is integrated with the university hospital and so it's working in education in clinical trials and diagnostic activity. And then we have several second-level masters, especially here today we are speaking about the second-level master in drug design and synthesis of our department. Our department has even two schools, two PhD schools, one in chemical and pharmaceutical sciences and the other one it's a school of Pegaso in biochemistry and molecular biology. Both PhD schools are in English. And here you can find some of the teaching stuff in our department that is from different academies in Italy, in Europe, and all over the world and research center mutually located in Italy and different companies that are involved in the teaching activities and in the education of our students. The research activity here in the development of entomology, chemistry, robotics, metabolism, butchery, biology, biomarkers, immunology, and more generally in cell and molecular biochemistry, molecular biology, vaccine, biotechnology, data analysis, side-by-food, biomaterials, and biocompatibility as well as intranomic and post-genomic and structural biology. Obviously my research activity is more focusing drug design and synthesis. That's why I'm the director of the second-level master in drug design and synthesis. And we are we work in collaboration with different universities here. There are some Erasmus programs that are activated all over the Europe from our department. These are just few of the ones we have. So for the students, even for the master students, there is the possibility to spend a period abroad to do their own research activity or exams in this university, which has some Erasmus agreement with our department. So moving towards one important news of our department is the second cycle master degree in sustainable industrial pharmaceutical technology, which is a completely new course. It's the first in Europe, which is focused on the socio-environmental economic sustainability of the production of drugs. This is an important part because as I told you just a few minutes ago, Italy, it's one of the most important countries in drug development and pharmaceutical industry. And nowadays, the sustainability of the processes in pharmaceutical companies are a very, very important focus for the future development of in the pharmaceutical field. That's why we start with this new course, which is trying to develop new professionals, polyvalent, multi-component and cross-cutting professional people that are able to work in the biotech pharmaceutical sector. So they have different subjects to be studied that are moving from pharmaceutical products to biobased products, sustainability, bioinformatics and victim analysis, as well as international management and regulatory affairs. Just because we need to develop all the soft skills that are necessary in our day to work in this pharmaceutical world, which is moving and changing pretty fast. We are trying to apply in this course a new educational model by applying active learning activities, active learning techniques, by using teamwork and system and different individual programs related to the need, the different needs of any single student. The course is two-year and it's a second cycle master degree. It's located in Siena, it's in English and it's to access, you need a bachelor degree. So the first year courses are here reported and the second year courses, as you can see, are most based on students choice courses in such a way that any students can decide which is its own field of interest and can build up its own educational course. And then there is a stage with some free seminars after the stage. They have to write down for final dissertation a kind of thesis and then they get to the degree. One of the main of the special project of this course, it's a part of the achievement of the fifth goal of sustainable development, which is represented by gender equality and empower all women and girls. Especially we have a special program for women in science. So moving forward to the master induct design and synthesis, I'm the director of, you can, we start to work with this master, which is at the end edition. It's related especially to the, to how pharmaceutical companies are important in Italy. And the fact that they want to have people working in the fields that have a strong background in different fields. And usually they are not able to reach these very multidisciplinary backgrounds just by a bachelor or a master degree. That's why we start some years ago with the master in drug design and synthesis as the production and the development of new drugs. It's quite complicated. As you can see here starting from 10,000 compounds, you arrive at the end to obtain one active molecules that after years, after 20 years, it can be eventually able to became a drug. In all these steps reported over here, you need aspers. And so what we want to do with the master in drug design and synthesis is the education of high-level researcher, researchers with a well-balanced theoretical and practical knowledge on chemical, analytical, biological, and biotechnological research to work in pharmaceutical industry. The students need to have a master degree in chemical or biological fields and they need to be interested in pharmaceutical and biotechnological industry and topics. How the master works? So it's an 80-month course. It's a several-level master and it's held in Italian and English languages. It's composed by different activities. So there are 200 hours of frontal lessons, approach and teamwork to be presented by the students, a midterm exam and a stage and a final dissertation once a thesis on the base of the stage activities it's wrote down and it's presented to commission. For the frontal lessons, they are blended. That's mean that they are both in presence and online and they are divided in two sessions, the first one and the second one. I'll show you just some of the topics of our master, which are in synthesis of new compounds, catalysis and bio-metallysis, in chemistry as a special focus. As nowadays, it's not important to synthesize and to develop new drugs but you need to develop them in a very sustainable manner. Then you have some a part of computational and medicinal chemistry, analytical chemistry, especially for the analysis of drugs, pharmacology and regulatory affairs, which is an important task, especially nowadays. We know with the problems related to the COVID-19 vaccines, how important to have experts able to discuss about the different topics, the different issues that can move from the production of a new vaccine of a new molecule to its development and to clinical trials. Then we have a part of psychology, especially for angle management and teamwork management and a part of leadership development. This is a new part I recently introduced inside the master activities. Here you can see some example of the first section of frontal lessons of the master of this year master, which is composed by different lessons from both companies and academic professor. We have a part of natural products, synthesis and development to obtain new drugs, drug-like properties and drug discoveries and then all the communication skills and biostructural analysis to help people to work together. This is an important part made by Professor Cugini, who is a professor in this field working for many pharmaceutical companies. Then we work on antibiotics, resistance, process validation, economics of pharmaceuticals, then all the part of green chemistry and catalysis, which is crucial nowadays to develop new drugs, then all the new pharmaceutical stuff and the drug metabolism that Adam has studied. For the second session that we will have in June, we are moving to all the computational part related to cheminformatics applied to NCMS analysis in drug discovery, as well as in the development of research botanology. As here in Siena, we have the GSK company, which is directly involved even in the production of additives for COVID-19 vaccines. In fact, we have a special part related to SARS-CoV-2 infections here. As in the scanalive sciences, the foundation I spoke to you about a few minutes ago, is developing new monoclonal antibodies for the treatment of COVID-19. So here we will have the most important experts in the field, speaking with our students and teaching them the most modern and crucial issues for the development of these new drugs. Then we have a part of bioconvocation techniques and molecular and cellular imaging, as well as some lessons dedicated to intellectual properties, research and development and to computer-rated drug design. All these parts will be composed by a theoretical part, as well as an experimental one in which the students can start and can learn how to use different softwares for computational chemistry, development and drug design, especially. Here you can find some of our professors from the King's College in London, from the University of Siena and many pharmaceutical companies such as Chiesi, Alpha Sigma, Indiana, AXEM, but we have even IFA, which is an important agency in Italy, such as the FDA in the U.S., for the old regulatory affairs. We have people from the University of Vienna and GSK, as well as from the Stemalife Science and from the Consigna Nazionale Delirici Arcade in Italy. For the master degree, the frequency is mandatory for the 80 percent of classes, as well as the stage, which is an experimental one that can be done in both academies, research centers, as well as in company. It's 625 hours. Then we have a middle test. It will be in June and the discussion of our final pieces that can be done in a match next year. Several companies have some agreement with the University of Siena and here are reported just some of the ones that host our students for the stages. We have Aqrit, Dorbe, Chiesi, Phylogena, Alpha Sigma, GSK, ERBM, which is directly involved in the development with us for the AstraZeneca, one of the most important COVID vaccines we have actually in Italy, Vismagheri, and many others such as Sanofi from the Institute, Mario Negri, Milan, the Scandalife Sciences. We have several companies. These are just a few of the ones that are working with us with our students for the stages. The stages, most of our students prefer to do a stage in industry, the 70% while the 20% is doing the stage in academy and the 10% in other research centers or kind of foundation. The occupational activity of our students, it's very high. The 45% of them, it's working in industry and 25% of them access. They decide to access after their master to a PhD program. Other are involved in other fields. That means it feels related to analytical chemistry. They are probably trying to open the Giron small companies to furnish some services to the pharmaceutical companies as well. The recruitment for the master and drug design and synthesis for the next edition, which will be the 9th one, 19th one, will be in November of this year to start all the activities in February 2022. So there is enough time to decide to participate. So in general, what you will get by being recruited for this master is to learn something new about not only basic research, but even very applied research. Having real problem solving activities with your groups and teachers from all companies and academies. And you will have the chance to decide in which different fields of the pharmaceuticals development you want to work to be able to go on with your dreams and to be happy and love your work. So for the next edition, stay tuned. Here you can find the website of the master in which you can find all the information you need, even for recruitment. And here just a picture of Siena and its landscape here is the center of our university. It's located just here behind Dazzali's campus. And I hope to see all of you in Siena and to have the chance to meet you as a student of our master. If you have any questions, I am here to answer. Thank you.